FROM THE 2015 ASCO BREAST CANCER SYMPOSIUM

Well-documented racial disparities in survival of patients with HER2+ breast cancer diminished after FDA approval of trastuzumab, according to research presented at the 2015 ASCO breast cancer symposium.

A retrospective study identified 32,597 cases of HER2+ breast cancer from the California Cancer Registry, and divided them into early (diagnosed 2000-2006) and late (diagnosed 2006-2012) cohorts. In the early cohort, diagnosed before trastuzumab was available, black patients had an increased risk of mortality (hazard ratio, 1.32; 95% confidence interval, 1.16-1.49), compared with whites. In the late cohort there were no survival differences based on race.

“Although we were unable to document use of anti-HER2 treatment, the era of adjuvant trastuzumab appears to have attenuated the black/white disparity in HER2-positive breast cancer,” wrote Dr. Vincent Caggiano, hematologist at Sutter Medical Center Sacramento, California, and colleagues in a meeting abstract.

The study analyzed risk of mortality, adjusted for stage, grade, age, and socioeconomic status, for African Americans, Hispanics, Asian/Pacific Islanders, and American Indians, compared with white patients. Considering estrogen-receptor and progesterone-receptor status, the combination of all HER2+ subtypes (ER+/PR+/HER2+, ER-/PR+/HER2+, ER+/PR-/HER2+, ER-/PR-/HER2+), showed increased risk for black patients before 2006. The ER-/PR-/HER2+ subtype showed no racial disparities for either cohort. The highest risk (HR, 1.43; 95% CI, 1.17-1.75) was observed for black patients of the ER+/PR+/HER2+ subtype diagnosed before 2006.

Ads

You May Also Like

FDA sunscreen guidance calls for maximal use trials

The Food and Drug Administration has released final industry guidance for nonclinical sunscreen manufacturers, ...

Onstep hernia repair decreased postop pain during sexual activity

FROM SURGERY The Onstep technique for inguinal hernia repair is associated with a lower ...